Source 1primary paper2025MED
Toolkit/antisense oligonucleotide-mediated splicing correction
antisense oligonucleotide-mediated splicing correction
Also known as: antisense oligonucleotide-mediated splicing correction
Taxonomy: Mechanism Branch / Component. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Emerging therapeutic strategies aim to counteract these processes through antisense oligonucleotide-mediated splicing correction
Usefulness & Problems
Why this is useful
This strategy aims to correct pathogenic alternative splicing events that generate resistance-associated isoforms. In the review abstract, it is presented as an emerging way to counteract antigenic plasticity.; counteracting splicing-mediated resistance to antibody-based therapies; restoring antigen expression in RNA-informed precision antibody therapy strategies
Source:
This strategy aims to correct pathogenic alternative splicing events that generate resistance-associated isoforms. In the review abstract, it is presented as an emerging way to counteract antigenic plasticity.
Source:
counteracting splicing-mediated resistance to antibody-based therapies
Source:
restoring antigen expression in RNA-informed precision antibody therapy strategies
Problem solved
It is proposed to address splicing-driven loss or remodeling of therapeutic antigens that contributes to immune escape. The intended outcome is restoration of antigen expression or reduction of resistance-associated isoforms.; aberrant splicing that promotes immune escape and resistance
Source:
It is proposed to address splicing-driven loss or remodeling of therapeutic antigens that contributes to immune escape. The intended outcome is restoration of antigen expression or reduction of resistance-associated isoforms.
Source:
aberrant splicing that promotes immune escape and resistance
Problem links
aberrant splicing that promotes immune escape and resistance
LiteratureIt is proposed to address splicing-driven loss or remodeling of therapeutic antigens that contributes to immune escape. The intended outcome is restoration of antigen expression or reduction of resistance-associated isoforms.
Source:
It is proposed to address splicing-driven loss or remodeling of therapeutic antigens that contributes to immune escape. The intended outcome is restoration of antigen expression or reduction of resistance-associated isoforms.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Component: A low-level RNA part used inside a larger architecture that realizes a mechanism.
Techniques
Computational DesignTarget processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
It requires antisense oligonucleotides and a defined splicing event to target. The abstract does not specify delivery platform or dosing context.; requires a splicing defect amenable to oligonucleotide-mediated correction
The abstract does not show that it solves non-splicing resistance mechanisms such as phenotypic switching or heterogeneous target expression. It also does not provide evidence for any one cancer setting.; specific target, delivery requirements, and efficacy details are not provided in the abstract
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Aberrant activity of splicing regulators disrupts canonical exon selection, leading to altered receptor signaling or secretion of soluble decoy isoforms that evade immune recognition.
Emerging strategies to counteract splicing-mediated resistance include antisense oligonucleotide-mediated splicing correction, pharmacologic modulation of splicing regulators, and isoform-selective antibody or CAR-T designs.
Understanding splicing-driven antigenic plasticity provides a framework for RNA-informed precision antibody therapies designed to restore antigen expression, overcome immune escape, and enhance durable clinical responses.
Approval Evidence
1 source2 linked approval claimsfirst-pass slug antisense-oligonucleotide-mediated-splicing-correction
Emerging therapeutic strategies aim to counteract these processes through antisense oligonucleotide-mediated splicing correction
Source:
therapeutic strategysupports
Emerging strategies to counteract splicing-mediated resistance include antisense oligonucleotide-mediated splicing correction, pharmacologic modulation of splicing regulators, and isoform-selective antibody or CAR-T designs.
Source:
translational frameworksupports
Understanding splicing-driven antigenic plasticity provides a framework for RNA-informed precision antibody therapies designed to restore antigen expression, overcome immune escape, and enhance durable clinical responses.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Source:
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Source-backed strengths
directly targets splicing defects described as a resistance mechanism
Source:
directly targets splicing defects described as a resistance mechanism
Compared with CAR-T
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Shared frame: source-stated alternative in extracted literature
Strengths here: directly targets splicing defects described as a resistance mechanism.
Relative tradeoffs: specific target, delivery requirements, and efficacy details are not provided in the abstract.
Source:
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Compared with CAR-T cells
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Shared frame: source-stated alternative in extracted literature
Strengths here: directly targets splicing defects described as a resistance mechanism.
Relative tradeoffs: specific target, delivery requirements, and efficacy details are not provided in the abstract.
Source:
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Compared with CAR-T therapy
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Shared frame: source-stated alternative in extracted literature
Strengths here: directly targets splicing defects described as a resistance mechanism.
Relative tradeoffs: specific target, delivery requirements, and efficacy details are not provided in the abstract.
Source:
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Shared frame: source-stated alternative in extracted literature
Strengths here: directly targets splicing defects described as a resistance mechanism.
Relative tradeoffs: specific target, delivery requirements, and efficacy details are not provided in the abstract.
Source:
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Compared with chimeric antigen receptor T cells
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Shared frame: source-stated alternative in extracted literature
Strengths here: directly targets splicing defects described as a resistance mechanism.
Relative tradeoffs: specific target, delivery requirements, and efficacy details are not provided in the abstract.
Source:
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Compared with Chimeric antigen receptor T-cell therapy
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Shared frame: source-stated alternative in extracted literature
Strengths here: directly targets splicing defects described as a resistance mechanism.
Relative tradeoffs: specific target, delivery requirements, and efficacy details are not provided in the abstract.
Source:
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Compared with isoform-selective antibody or CAR-T designs
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Shared frame: source-stated alternative in extracted literature
Strengths here: directly targets splicing defects described as a resistance mechanism.
Relative tradeoffs: specific target, delivery requirements, and efficacy details are not provided in the abstract.
Source:
The abstract contrasts this approach with pharmacologic modulation of splicing regulators and isoform-selective antibody or CAR-T designs.
Ranked Citations
- 1.